CD30在EBV阳性弥漫性大B细胞淋巴瘤中的表达及其预后意义

目的:探讨CD30在EBV阳性弥漫性大B细胞淋巴瘤(EBV-positive diffuse large B-cell lymphoma,EBV+DLBCL)中的表达及预后意义。方法:回顾性分析322例DLBCL中EBV+DLBCL与EBV-DLBCL病例临床病理参数之间的关系,以及CD30在EBV+DLBCL中的表达及预后意义。结果:CD30在EBV+DLBCL病例中的表达多于EBV-DLBCL病例(P=0.002);EBV-DLBCL中双表达的病例多于EBV+DLBCL(P=0.044);在63例EBV+DLBCL中,CD30阳性表达多见于B症状患者(P=0.015);另外有2例EBV+DLBCL病例出现BCL6基因重排。随访139例患者中,共表达CD30和EBER的患者预后较差(P=0.002);在EBV+DLBCL中,CD30阳性提示预后更差(P=0.028)。结论:CD30在EBV+DLBCL病例中具有较高的表达率,且与患者不良预后相关,进一步为靶向药物的使用提供理论依据。

Expression and prognostic significance of CD30 protein in EBV-positive diffuse large B-cell lymphoma

Objective:To investigate expression and prognostic significance of CD30 protein in EBV-positive diffuse large B-cell lymphoma(EBV+DLBCL).Methods:The relationship of clinicopathological data in 322 DLBCL(EBV+DLBCL and EBV-DLBCL) cases were analyzed restrospectively.Meanwhile,we assessed the expression and prognostic significance of CD30 in EBV+DLBCL.Results:The expression of CD30 in EBV+DLBCL was higher than that in EBV-DLBCL(P=0.002).MYC/BCL2 double expression were commonly been seen in EBV-DLBCL compared with EBV+DLBCL(P=0.044).Strong immunoreactivity of CD30 was associated with B-symptoms in 63 EBV+DLBCL (P=0.015).Besides,we found BCL6 gene rearrangement in 2 EBV+DLBCL.Of the 139 patients were followed up,CD30 expression combined with EBV conferred an inferior outcome(P=0.002).The positive expression of CD30 indicated a worse prognosis in EBV+DLBCL(P=0.028).Conclusion:CD30 expression level in EBV+DLBCL is significantly high,which is associated with poor prognosis,providing a theory basis for the use of targeted drugs.